RxDoctor Payments Data

Jeffrey Rule, OD

Optometrist · Lansing, MINPI 1932290962

Payments from drug & device makers

$1,791in general payments, 2019–2025

Across 92 payments — averaging $19.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$474
  • Alcon$348
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$221
  • Oyster Point Pharma, Inc.$152
  • Bausch & Lomb Americas Inc.$144
  • Tarsus Pharmaceuticals, Inc.$104
  • plus $349 from 8 others

What the payments were for

  • Food & beverage$1,791100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,791 in reported general payments places this provider in the 80th percentile of 1,523 optometrist providers in Michigan.

See all optometrist providers in Michigan

Medicare billing

Part B allowed, 2024
$46,247
Medicare patients
212
Services billed
649

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost54$28,522
RestasisCyclosporine16$20,813
XiidraLifitegrast11$17,521
Cyclosporine17$15,831
CombiganBrimonidine Tartrate/Timolol20$10,051
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol22$8,232
Brimonidine Tartrate49$5,256
Fluorometholone31$4,300
Latanoprost163$4,022
Prednisolone Acetate46$3,274
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat28$848
Dorzolamide Hcl20$361
Timolol Maleate19$350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$474$59,38690 claims
Bausch & Lomb Americas Inc.Xiidra$144$17,52111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,523 optometrist providers in Michigan.

Other optometrist in Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →